All In Biotech

Drug Trial Radar · NCT04902872

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

69

Actual

Start

May 3, 2021

Primary completion

Jun 24, 2025

Study completion Jun 24, 2025

Sponsor

Lead sponsor
Cybrexa TherapeuticsIndustry
Sponsor type
Industry
First posted
May 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.

Conditions

  • Solid Tumor, Adult
  • Epithelial Ovarian Cancer
  • Small Cell Lung Carcinoma
  • Breast Cancer
  • Colorectal Cancer
  • Pancreas Cancer
  • Appendix Cancer
  • Non-small Cell Lung Cancer
  • Gastric Cancer
  • Esophagus Cancer
  • Urothelial Carcinoma
  • Sarcoma

Interventions

  • CBX-12Drug

    CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Incidence of treatment-emergent adverse events (TEAEs)Time frame: Through the end of study, estimated as 6 months
  2. Phase 1: Recommended Phase 2 Dose for Daily x 3 every 3 weeks schedule of CBX-12 (Schedule B)Time frame: 15 months
  3. Phase 1: Recommended Phase 2 Dose for Once Weekly schedule of CBX-12 (Schedule C)Time frame: 15 months
  4. Phase 1: Recommended Phase 2 Dose for Once Every 3 Weeks schedule of CBX-12 (Modified Schedule B)Time frame: 15 months
  5. Phase 2: Overall response rate (ORR)Time frame: Through the end of study, estimated as 6 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Yale Cancer Center

    New Haven, Connecticut

  • NEXT Oncology

    Austin, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • NEXT Oncology

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.